Inhibikase Therapeutics (NYSE:IKT) vs. LadRx (OTCMKTS:CYTR) Critical Contrast

Inhibikase Therapeutics (NYSE:IKT) and LadRx (OTCMKTS:CYTR) are both small-cap medical companies, but which is the superior business? We will compare the two businesses based on the strength of their institutional ownership, valuation, earnings, profitability, analyst recommendations, dividends and risk.

Valuation & Earnings

This table compares Inhibikase Therapeutics and LadRx”s top-line revenue, earnings per share (EPS) and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Inhibikase Therapeutics	N/A	N/A	-$19.03 million	($2.67)	-0.62
LadRx	N/A	N/A	-$6.70 million	($0.15)	N/A

Inhibikase Therapeutics is trading at a lower price-to-earnings ratio than LadRx, indicating that it is currently the more affordable of the two stocks.

Insider & Institutional Ownership

3.8% of Inhibikase Therapeutics shares are held by institutional investors. Comparatively, 0.1% of LadRx shares are held by institutional investors. 7.3% of Inhibikase Therapeutics shares are held by company insiders. Comparatively, 12.8% of LadRx shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company is poised for long-term growth.

Risk & Volatility

Inhibikase Therapeutics has a beta of 0.89, suggesting that its stock price is 11% less volatile than the S&P 500. Comparatively, LadRx has a beta of 1.96, suggesting that its stock price is 96% more volatile than the S&P 500.

Profitability

This table compares Inhibikase Therapeutics and LadRx’s net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
Inhibikase Therapeutics	N/A	-350.63%	-201.82%
LadRx	N/A	-67.61%	-45.39%

Analyst Ratings

This is a breakdown of recent recommendations and price targets for Inhibikase Therapeutics and LadRx, as provided by MarketBeat.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Inhibikase Therapeutics	0	1	1	0	2.50
LadRx	0	0	0	0	0.00

Inhibikase Therapeutics presently has a consensus target price of $6.50, suggesting a potential upside of 291.57%. Given Inhibikase Therapeutics’ stronger consensus rating and higher probable upside, equities analysts clearly believe Inhibikase Therapeutics is more favorable than LadRx.

Summary

LadRx beats Inhibikase Therapeutics on 7 of the 11 factors compared between the two stocks.

About Inhibikase Therapeutics

Inhibikase Therapeutics, Inc., a clinical-stage pharmaceutical company, develops therapeutics for Parkinson’s disease and related disorders. Its lead product candidate is IkT-148009, a non-receptor Abelson tyrosine kinase inhibitor, which is in Phase 2a clinical trials to the treatment of Parkinson’s disease and gastrointestinal tract. The company is also developing IkT-001Pro, a prodrug of the anticancer agent imatinib mesylate to treat stable phase chronic myelogenous leukemia. Inhibikase Therapeutics, Inc. has research and development collaborations with Johns Hopkins University, Arizona State University, and Michigan State University; and a collaborative research and development agreement with Sphaera Pharma Pte. Ltd. The company was founded in 2008 and is headquartered in Atlanta, Georgia.

About LadRx

LadRx Corporation, a biopharmaceutical company, engages in the discovery and development of therapeutics to treat patients with cancer. The company's advanced drug conjugate, aldoxorubicin that is in late-stage clinical trials is a version of anti-cancer drug doxorubicin. Its pre-clinical therapeutics comprise linker activated drug releases 7, 8, 9, and 10 targeted against cancer The company was formerly known as CytRx Corporation and changed its name to LadRx Corporation in September 2022. LadRx Corporation was incorporated in 1985 and is headquartered in Los Angeles, California.